Login
Navigate Fool.com
Will SNY beat
the market?

Sanofi (ADR) (NYSE: SNY)

Community Rating: 5 Stars: The Best

50.97 -1.06 (-2.04%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $51.71
Previous Close $52.03
Daily Range $50.83 - $51.73
52-Week Range $46.95 - $54.64
Market Cap $135.0B
P/E Ratio 27.97
Dividend (Yield) $1.91 (2.5%)
Ex-Dividend Date
Dividend Pay Date
05/07/14
06/05/14
Volume 671,233
Average Daily Volume 889,695
Current FY EPS $3.49

How do you think SNY
will perform against the market?

Top SNY Bull/Bear Pitches

 

aeprescott89 (0)
Submitted May 16, 2013

Aging population (especially in Europe) will continue to increase dependency on prescription medications, also doing some great things with R&D.

0 Replies Reply Report this Post
 

anton123 (0)
Submitted June 25, 2009

UBS’s Amusa has a “sell” rating on Sanofi and has a “buy” rating on Novo Nordisk A/S, which produces a rival diabetes treatment called Levemir. “We have to be careful not to taint a medicine which he … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Biogen Stock's Tecfidera Embarrasses Wall Street

Sales of Biogen's (BIIB) MS drug Tecfidera soared again last quarter as it won market share away from competing oral MS drugs from Novartis (NVS) and Sanofi (SNY).

Could This 1 Lawsuit Destroy Biogen Idec Stock?

Sanofi (SNY) and Novartis (NVS) generic units are among those challenging the dosing patent on Biogen's (BIIB) Tecfidera.

Pre-Market Most Active for Jul 21, 2014 : EMC, AAPL, ORAN, FB, SNY, ERIC, KNDI, ABBV, PHG, AKS, GPR

Pre-Market Most Active for Jul 21, 2014 : EMC, AAPL, ORAN, FB, SNY, ERIC, KNDI, ABBV, PHG, AKS, GPRO, QQQ

India Just Did What Millions of Americans Wish the U.S. Government Would Do

India's National Pharmaceutical Pricing Authority levies a game-changing decision this past week meant to improve access to branded medications. Find out how this action could both help and hurt India's citizens, and why it would be nearly impossible to implement in the United States.

Microsoft Layoffs Include an End to Original Video Production

The cuts are part of some wide-sweeping changes at the technology giant.

2.5 Billion People Threatened by This Disease: How We're Fighting Back

And how a company can do well by doing good.

This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something

Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.

Regeneron, Sanofi Drug Holds Up in Eczema Study

Read below for more on this exciting story.

Wednesday’s Top Biotech Stories: Celgene, AbbVie, Shire, and Sanofi

Celgene, AbbVie, Shire, and Sanofi are the top biotech stories to follow this Wednesday morning.

Growth and Dividends: Europe's Best Pharma Stock

Read below to find out which stock it is.

See More SNY News...

Sector

Healthcare

Industry

Drugs

Sanofi (ADR) (SNY) Description

A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Website: http://www.sanofi.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks